Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Buy
55
ATRA Quote, Financials, Valuation and Earnings
Last price:
$8.57
Seasonality move
:
-1.48%
Day range:
$8.32 - $9.00
52-week range:
$5.01 - $18.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.38x
P/B ratio:
--
Volume:
39.4K
Avg. volume:
71.3K
1-year change:
-32.84%
Market cap:
$51.1M
Revenue:
$128.9M
EPS (TTM):
-$3.72
Analysts' Opinion
-
Consensus RatingAtara Biotherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.00, Atara Biotherapeutics has an estimated upside of 86.48% from its current price of $8.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $8.58.
Fair Value
-
According to the consensus of 5 analysts, Atara Biotherapeutics has 86.48% upside to fair value with a price target of $16.00 per share.
ATRA vs. S&P 500
-
Over the past 5 trading days, Atara Biotherapeutics has underperformed the S&P 500 by -7.46% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Atara Biotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atara Biotherapeutics has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Atara Biotherapeutics reported revenues of $98.1M.
Earnings Growth
-
Atara Biotherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Atara Biotherapeutics reported earnings per share of $3.50.
Enterprise value:
37.3M
EV / Invested capital:
-0.68x
Price / LTM sales:
0.38x
EV / EBIT:
--
EV / Revenue:
0.19x
PEG ratio (5yr expected):
-0.16x
EV / Free cash flow:
-0.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$160.3M
Return On Assets:
-13.11%
Net Income Margin (TTM):
-7.83%
Return On Equity:
-2818.48%
Return On Invested Capital:
-2818.48%
Operating Margin:
39.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $57.5M | $34.7M | $199.7M | $27.4M | $98.1M | |
| Gross Profit | $57.3M | $24M | $160.3M | $25.4M | $77.7M | |
| Operating Income | -$267.3M | -$232.2M | -$13.4M | -$31.2M | $38.8M | |
| EBITDA | -$208M | -$223M | -$5.7M | -$29.2M | $40.8M | |
| Diluted EPS | -$52.00 | -$52.88 | -$3.72 | -$5.65 | $3.50 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $464.3M | $314.4M | $224.2M | $106.4M | $27.2M | |
| Total Assets | $529.6M | $397.3M | $302.1M | $165.3M | $62M | |
| Current Liabilities | $84.2M | $101.6M | $67.9M | $180.7M | $47.9M | |
| Total Liabilities | $130.6M | $173M | $237.1M | $263.6M | $117.1M | |
| Total Equity | $399M | $224.3M | $65M | -$98.3M | -$55.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$224.3M | -$184.2M | -$67.2M | -$29.6M | -$28.1M | |
| Cash From Investing | $136.7M | $144.6M | $11.1M | $14.7M | $17.2M | |
| Cash From Financing | $33.5M | $25.9M | $34.9M | $24.1M | -$250K | |
| Free Cash Flow | -$226.3M | -$185.1M | -$67.2M | -$29.7M | -$28.1M | |
ATRA
Sector
Market Cap
$51.1M
$32.3M
Price % of 52-Week High
45.87%
46.89%
Dividend Yield
0%
0%
Shareholder Yield
-101.1%
-0.66%
1-Year Price Total Return
-32.84%
-37.62%
Beta (5-Year)
0.187
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.88
200-day SMA
Sell
Level
$8.83
Bollinger Bands (100)
Buy
Level
6.32 - 8.44
Chaikin Money Flow
Sell
Level
-2.6M
20-day SMA
Buy
Level
$8.08
Relative Strength Index (RSI14)
Buy
Level
58.44
ADX Line
Buy
Level
36.8
Williams %R
Neutral
Level
-47.3684
50-day SMA
Buy
Level
$7.26
MACD (12, 26)
Buy
Level
0.47
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
14.9K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-28.1669)
Sell
CA Score
(Annual)
Level (-8.3306)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (14.3775)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Stock Forecast FAQ
In the current month, ATRA has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ATRA average analyst price target in the past 3 months is $16.00.
-
Where Will Atara Biotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atara Biotherapeutics share price will rise to $16.00 per share over the next 12 months.
-
What Do Analysts Say About Atara Biotherapeutics?
Analysts are divided on their view about Atara Biotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atara Biotherapeutics is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Atara Biotherapeutics's Price Target?
The price target for Atara Biotherapeutics over the next 1-year time period is forecast to be $16.00 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ATRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atara Biotherapeutics is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ATRA?
You can purchase shares of Atara Biotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atara Biotherapeutics shares.
-
What Is The Atara Biotherapeutics Share Price Today?
Atara Biotherapeutics was last trading at $8.57 per share. This represents the most recent stock quote for Atara Biotherapeutics. Yesterday, Atara Biotherapeutics closed at $8.58 per share.
-
How To Buy Atara Biotherapeutics Stock Online?
In order to purchase Atara Biotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is down 89.92% over the past day.
Sell
16
VEON alert for Jun 17
VEON [VEON] is up 4.61% over the past day.
Buy
64
INOD alert for Jun 17
Innodata [INOD] is up 13.78% over the past day.
